Treatment of severe lupus nephritis: the new horizon. (Q38271125)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Treatment of severe lupus nephritis: the new horizon (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Tak Mao Chan

series ordinal

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

25 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

46-61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan.

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Survival analysis and causes of mortality in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Lupus nephritis: lessons from murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Value of a complete or partial remission in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The prognosis of lupus nephritis in African-Americans: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Severe lupus nephritis: racial differences in presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Cyclophosphamide: new approaches for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Different targets for treating focal segmental glomerular sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Tacrolimus in the treatment of idiopathic nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

B-cell depletion in the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

21 January 2018

12 December 2020

Current immunotherapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Hydroxychloroquine: from malaria to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The biology behind the new therapies for SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The spectrum of renal thrombotic microangiopathy in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The prognosis and pathogenesis of severe lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Pathogenetic features of severe segmental lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Overview of lupus nephritis management guidelines and perspective from Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Pharmacokinetics of mycophenolic acid in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Factors affecting outcome and prognosis in membranous lupus nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Malignancy following treatment of rheumatoid arthritis with cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Prognostic factors of lupus myelopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil for remission induction in severe lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment of idiopathic membranous nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Intractable ulceration in a patient with lupus erythematosus profundus successfully treated with cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term data on tacrolimus treatment in lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Biological therapy for lupus nephritis-tribulations and trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mizoribine: a new approach in the treatment of renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Mizoribine requires individual dosing due to variation of bioavailability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

High-dose mizoribine treatment for adolescents with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Study of the efficacy of mizoribine in lupus nephritis in Chinese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

To TDM or not to TDM in lupus nephritis patients treated with MMF?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Long-term outcome of Chinese patients with membranous lupus nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.215

Lupus membranous nephropathy: long-term outcome

31 March 2020

1 reference

12 December 2020

Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice

1 reference

12 December 2020

Chloroquine inhibits proinflammatory cytokine release into human whole blood.

1 reference

12 December 2020

Attenuation of murine lupus nephritis by mycophenolate mofetil.

1 reference

12 December 2020

Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted?

1 reference

12 December 2020

The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.

1 reference

12 December 2020

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

1 reference

12 December 2020

Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.

1 reference

12 December 2020

The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

1 reference

12 December 2020

Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy

1 reference

12 December 2020

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

1 reference

12 December 2020

High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients

1 reference

12 December 2020

Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.

1 reference

12 December 2020

Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus

1 reference

12 December 2020

Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.

1 reference

12 December 2020

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2014.215

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25421826%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference